Biotech may have side-stepped CFIUS’ worst case scenario
The inability to define emerging and foundational technology means most foreign investments in U.S. biotechs will avoid scrutiny
The Commerce Department’s inability to define emerging and foundational technologies means most foreign investments in U.S. biotechs will avoid government scrutiny.
So far, biotech has avoided the nightmare scenario in which almost any private company seeking foreign investment would come under government scrutiny. Recently proposed legislation could inject additional uncertainty, however, by changing who gets to decide which technologies are critical to national security.
The expansion of the jurisdiction of the Committee on Foreign Investment in the United States (CFIUS) in 2018 raised alarm across industries as it gave CFIUS power to investigate many